Takeda Pharmaceutical annual depreciation and amortization
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Takeda Pharmaceutical Depreciation & Amortization Growth & History (TAK)
Takeda Pharmaceutical's depreciation and amortization was ¥721.13B for fiscal 2026.
View full Takeda Pharmaceutical company overviewTakeda Pharmaceutical annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | ¥721.13B | −¥40.27B | −5.29% |
| 2025 | 2025-03-31 | ¥761.40B | ¥33.39B | +4.59% |
| 2024 | 2024-03-31 | ¥728.00B | ¥63.60B | +9.57% |
| 2023 | 2023-03-31 | ¥664.40B | ¥81.25B | +13.93% |
| 2022 | 2022-03-31 | ¥583.15B | ¥23.48B | +4.20% |
| 2021 | 2021-03-31 | ¥559.67B | −¥23.98B | −4.11% |
| 2020 | 2020-03-31 | ¥583.65B | ¥335.96B | +135.64% |
| 2019 | 2019-03-31 | ¥247.69B | ¥65.56B | +36.00% |
| 2018 | 2018-03-31 | ¥182.13B | ¥10.70B | +6.24% |
| 2017 | 2017-03-31 | ¥171.43B | — | — |
Takeda Pharmaceutical quarterly depreciation and amortization
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-03-31 | ¥163.87B | −¥25.90B | −13.65% |
| Q3 2026 | 2025-12-31 | ¥190.64B | — | — |
| Q2 2026 | 2025-09-30 | ¥184.98B | — | — |
| Q1 2026 | 2025-06-30 | ¥181.64B | — | — |
| Q4 2025 | 2025-03-31 | ¥189.77B | — | — |
Takeda Pharmaceutical depreciation and amortization trends
Over the last five fiscal years, Takeda Pharmaceutical's depreciation and amortization increased from ¥559.67B to ¥721.13B, a change of ¥161.46B. The latest reported quarter, Q4 2026, shows ¥163.87B.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Takeda Pharmaceutical source filings ↗